Serono Rebif Interferon Beta-1a Treatment U.S. Launch Expected Mid-2002
Executive Summary
Serono expects to launch its interferon beta-1a treatment Rebif in the U.S. by mid-2002 after receiving the results from a head-to-head study comparing the multiple sclerosis biologic with Biogen's Avonex.
You may also be interested in...
Serostim Off-Label Use Under Scrutiny; Prosecutor Looks At Job Descriptions
The Boston U.S. Attorney's Office may be looking at employee job descriptions or performance criteria in its investigations of off-label promotion
Serostim Off-Label Use Under Scrutiny; Prosecutor Looks At Job Descriptions
The Boston U.S. Attorney's Office may be looking at employee job descriptions or performance criteria in its investigations of off-label promotion
Serono Serostim
Counterfeit Serostim has been reported by 10 to 12 patients, primarily in California. The only reported adverse reaction by patients who had injected the counterfeit product was skin irritation at the injection site, the company said. FDA's Office of Criminal Investigations is attempting to determine the distributor of the fake product. Somatropin is approved for AIDS wasting